RU2470665C2 - Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом - Google Patents

Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом Download PDF

Info

Publication number
RU2470665C2
RU2470665C2 RU2008132150/15A RU2008132150A RU2470665C2 RU 2470665 C2 RU2470665 C2 RU 2470665C2 RU 2008132150/15 A RU2008132150/15 A RU 2008132150/15A RU 2008132150 A RU2008132150 A RU 2008132150A RU 2470665 C2 RU2470665 C2 RU 2470665C2
Authority
RU
Russia
Prior art keywords
ser
thr
leu
gly
val
Prior art date
Application number
RU2008132150/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008132150A (ru
Inventor
Майкл КАВАНАФ
Чэн ЛЮ
Original Assignee
Новартис Аг
Ксома Текнолоджи Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг, Ксома Текнолоджи Лтд. filed Critical Новартис Аг
Publication of RU2008132150A publication Critical patent/RU2008132150A/ru
Application granted granted Critical
Publication of RU2470665C2 publication Critical patent/RU2470665C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2008132150/15A 2006-01-05 2007-01-04 Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом RU2470665C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75694406P 2006-01-05 2006-01-05
US60/756,944 2006-01-05
PCT/US2007/000405 WO2007081879A2 (en) 2006-01-05 2007-01-04 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis

Publications (2)

Publication Number Publication Date
RU2008132150A RU2008132150A (ru) 2010-02-10
RU2470665C2 true RU2470665C2 (ru) 2012-12-27

Family

ID=38219019

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008132150/15A RU2470665C2 (ru) 2006-01-05 2007-01-04 Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом

Country Status (12)

Country Link
US (1) US20090246208A1 (https=)
EP (2) EP2705854A1 (https=)
JP (2) JP5580535B2 (https=)
KR (1) KR20080083187A (https=)
CN (1) CN101534858A (https=)
AU (1) AU2007205048B2 (https=)
BR (1) BRPI0706314A2 (https=)
CA (1) CA2636149A1 (https=)
IL (1) IL192568A0 (https=)
RU (1) RU2470665C2 (https=)
TW (1) TW200738262A (https=)
WO (1) WO2007081879A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2609871C1 (ru) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство
RU2631486C1 (ru) * 2016-06-17 2017-09-22 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ получения противоопухолевого средства против метастазов костей в виде конъюгата белка-цитокина и аминобисфосфоната

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトcsf−1rに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
DK2734547T3 (en) 2011-07-18 2017-04-03 Univ Melbourne USE OF C-FMS ANTIBODIES
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN103044555B (zh) * 2012-07-05 2016-08-31 雷克塞德(苏州)生物医药有限公司 包含cFms胞外片段的融合蛋白质及其制备方法和应用
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
JP6577873B2 (ja) * 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ(イエレベ、バルセロナ)Fundacio Institut De Recerca Biomedica (Irb Barcelona) がんの転移の予後診断および処置のための方法
EA031471B1 (ru) 2013-04-12 2019-01-31 МорфоСис АГ Антитела, направленные на m-csf
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
RU2551622C1 (ru) * 2014-02-20 2015-05-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения опухолей позвоночника
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
MX2017008218A (es) 2014-12-22 2017-10-18 Five Prime Therapeutics Inc Anticuerpos anti-csf1r para tratar pvns.
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2153358C1 (ru) * 1999-11-10 2000-07-27 Центральный научно-исследовательский рентгенорадиологический институт МЗ России Способ лечения остеолитических метастазов
WO2005068503A2 (en) * 2004-01-07 2005-07-28 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
US20070249680A1 (en) * 2006-04-20 2007-10-25 Illig Carl R Inhibitors of c-fms kinase

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
DK0457804T3 (da) 1989-02-10 1996-09-23 Chiron Corp M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6025146A (en) * 1995-06-05 2000-02-15 Chiron Corporation Identification of M-CSF agonists and antagonists
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US20030199531A1 (en) 2001-07-19 2003-10-23 Todd Wipke YIGSR peptidomimetics and methods for using the same
EP1458400A1 (en) * 2001-12-13 2004-09-22 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
BRPI0314546B8 (pt) * 2002-09-27 2021-05-25 Zentaris Gmbh composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit.
DE60332483D1 (de) * 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー M−csf特異的モノクローナル抗体およびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2153358C1 (ru) * 1999-11-10 2000-07-27 Центральный научно-исследовательский рентгенорадиологический институт МЗ России Способ лечения остеолитических метастазов
WO2005068503A2 (en) * 2004-01-07 2005-07-28 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
US20070249680A1 (en) * 2006-04-20 2007-10-25 Illig Carl R Inhibitors of c-fms kinase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERENSON JR. Recommendations for zoledronic acid treatment of patients with bone metastases // Oncologist. 2005 Jan; 10(1):52-62 онлайн [найдено в Интернет Ha(http://theoncologist.alphamedpress. org/cgi/content/full/146/52)]. *
MORONY S. ET AL. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy // Endocrinology. 2005 Aug; 146(8):3235-43. Epub 2005, Apr 21 онлайн [найдено в Интернет на (http://endo.endojournals.org/cgi/content/full/146/3235)]. *
ДАРЬЯЛОВА С.Л. и др. Диагностика и лечение злокачественных опухолей. - М.: Медицина, 1993, с.72-85. *
ДАРЬЯЛОВА С.Л. и др. Диагностика и лечение злокачественных опухолей. - М.: Медицина, 1993, с.72-85. MORONY S. ET AL. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy // Endocrinology. 2005 Aug; 146(8):3235-43. Epub 2005, Apr 21 онлайн [найдено в Интернет на (http://endo.endojournals.org/cgi/content/full/146/3235)]. BERENSON JR. Recommendations for zoledronic acid treatment of patients with bone metastases // Oncologist. 2005 Jan; 10(1):52-62 онлайн [найдено в Интернет Ha(http://theoncologist.alphamedpress. org/cgi/content/full/146/52)]. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2609871C1 (ru) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство
RU2631486C1 (ru) * 2016-06-17 2017-09-22 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ получения противоопухолевого средства против метастазов костей в виде конъюгата белка-цитокина и аминобисфосфоната

Also Published As

Publication number Publication date
CA2636149A1 (en) 2007-07-19
JP2009522369A (ja) 2009-06-11
JP5580535B2 (ja) 2014-08-27
KR20080083187A (ko) 2008-09-16
EP1984024A2 (en) 2008-10-29
AU2007205048A1 (en) 2007-07-19
TW200738262A (en) 2007-10-16
CN101534858A (zh) 2009-09-16
US20090246208A1 (en) 2009-10-01
JP2012229271A (ja) 2012-11-22
AU2007205048B2 (en) 2013-07-04
WO2007081879A3 (en) 2007-09-07
RU2008132150A (ru) 2010-02-10
EP2705854A1 (en) 2014-03-12
IL192568A0 (en) 2011-08-01
BRPI0706314A2 (pt) 2011-03-22
WO2007081879A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
RU2470665C2 (ru) Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом
KR101307868B1 (ko) M-csf-특이적 단일클론 항체 및 그것의 사용
TWI774028B (zh) 抗alk2抗體及其用途
BR112019021411A2 (pt) métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
KR20160129698A (ko) 항-b7-h5 항체 및 이의 용도
US20230265203A1 (en) Use of anti-cd40 antibodies for treatment of lupus nephritis
JP2015013900A (ja) M−csf特異的モノクローナル抗体およびその使用
MX2013005477A (es) Variantes de fc silenciosas de los anticuerpos anti-cd40.
MX2014004449A (es) Tratamiento de enfermedad ocular.
BR112014028838A2 (pt) Usos de um anticorpo, método para fazer um anticorpo e anticorpos
KR20220007086A (ko) T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
US20240059781A1 (en) Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2023126445A1 (en) Anti-cd2 antibodies
HK1195254A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
MX2008008570A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
HK40093161A (zh) 抗ctla-4抗体药物组合物及其用途
EA039944B1 (ru) Применение антител к cd40 для лечения волчаночного нефрита

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160105